sampatrilat

Known as: N-(1-(2-carboxy-3-(N(2)-mesyllysylamino)propyl)-1-cyclopentylcarbonyl)tyrosine 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Angiotensin-1-converting enzyme (ACE) is a zinc metallopeptidase that consists of two homologous catalytic domains (known as nACE… (More)
  • table 1
  • table 2
  • figure 1
  • figure 3
  • figure 2
Is this relevant?
2016
2016
Sampatrilat is a vasopeptidase inhibitor that inhibits both angiotensin I-converting enzyme (ACE) and neutral endopeptidase. ACE… (More)
Is this relevant?
2003
2003
Sampatrilat is a novel vasopeptidase inhibitor that may offer a greater benefit than traditional angiotensin-converting enzyme… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2002
2002
Sampatrilat is a dual inhibitor of neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE), which is under… (More)
Is this relevant?
Review
2002
Review
2002
Vasopeptidase inhibitors are a new class of drugs that have dual inhibitory effects on two key enzymes involved in the metabolism… (More)
Is this relevant?
1999
1999
Our objective was to evaluate the safety and antihypertensive efficacy of sampatrilat, a novel dual inhibitor of both angiotensin… (More)
Is this relevant?
1998
1998
BACKGROUND The antihypertensive response to angiotensin-converting enzyme (ACE) inhibitors may be attenuated by a compensatory… (More)
Is this relevant?
1998
1998
Sampatrilat is a dual inhibitor of angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP) under development for the… (More)
Is this relevant?
1996
1996
1. The present studies compare the early renal response to (a) an endopeptidase-24.11 (E-24.11) inhibitor (candoxatrilat) (b) an… (More)
Is this relevant?